Elicera Therapeutics develops new cancer treatment with help of advanced cell lab in Flemingsberg
Uppsala-based Elicera Therapeutics is using the Pre-GMP core facility at Vecura in Flemingsberg as a first step in a study aimed at creating a new treatment for lymph node cancer.
The pre-GMP lab at Campus Flemingsberg makes it possible to use a new method to automate the process of genetically modifying cells for research studies.
“The facility allows us to benefit from a completely closed and automated system that reduces the workload for staff and further ensures quality,” says Magnus Essand, Research Director at Elicera.
In the Pre-GMP lab, the process can be developed and fine-tuned while staff at Vecura receive training in the new methods.
Activating the immune system
The establishment of Elicera Therapeutics was based on research conducted at Uppsala University with the aim of using modified cells – CAR-T cells – to develop new cancer treatments. Cells taken from patients develop the ability to activate the body’s own immune system in the fight against cancer.
The goal of the current study is to identify a treatment for patients with Non-Hodgkin’s lymphoma, a form of lymph node cancer.
“There are currently two approved treatments for the disease, but they don’t work for all patients. We hope that our treatment can also be used by these patients and prevent recurrence,” says Essand, adding: “We hope to develop a curative treatment for these patients.”
Elicera Therapeutics recently received a grant from the European Innovation Council (EIC) to help them grow further. In the future, there are plans to use the company’s findings to develop treatments for patients with brain cancer.
Read more on the Elicera Therapeutics homepage at: elicera.com.
Now Open: Flemingsberg Science Award STARTUP 2026
Do you have a business idea that can make a difference, locally or globally? Flemingsberg Science Award STARTUP is the competition for those who want to challenge their idea, gain valuable feedback from experienced experts, and take the first step toward building something real.
Campus Flemingsberg continues to grow – more students and strong collaboration in focus
Campus Flemingsberg remains one of Sweden’s most dynamic knowledge environments. Over the past year, the number of students has increased from 24,000 to approximately 27,000. The trend is clear: the campus’s broad academic profile continues to attract a growing number of students.
Limitless Potential: Winner of the Flemingsberg Science Award 2025
Young people in disadvantaged areas often face mental health challenges and a lack of support, which can lead to isolation and destructive choices. Limitless Potential, winner of the Flemingsberg Science Award IDEA 2025, has created a safe space where creativity and social entrepreneurship come together to support youth.
Alfa Laval strengthens Flemingsberg – establishes itself in a growing city of the future
In May 2025, Alfa Laval moved into its new office and innovation center, spanning approximately 20,000 square meters, together with around 700 employees. At the same time, the restaurant K-märkt opened, further expanding the range of services available in Flemingsberg. The Royal Swedish Opera and Dramaten, Alfa Laval, Restaurant Billmans, and K-märkt all represent important pieces of the puzzle in the development of Flemingsberg.
En nationell resurs för morgondagens behandlingar – nu är Karolinska ATMP Centrum invigt
Med ett tydligt budskap om framtidstro och ett kraftfullt samarbete invigdes Karolinska ATMP Centrum i Flemingsberg i slutet av augusti. Centret är ett samarbete mellan Karolinska Institutet och Karolinska Universitetssjukhuset, och kommer fungera som en nationell resurs för tillverkning av avancerade terapier (ATMP), där forskning, kliniska prövningar och behandlingar smidigt samverkar för att leverera banbrytande terapier till patienter.
